US6849656B1
(en)
|
1999-09-17 |
2005-02-01 |
Baylor University |
Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
EP1263763B1
(en)
|
2000-03-10 |
2007-07-25 |
Baylor University |
Tubulin binding ligands
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
PL371486A1
(en)
|
2002-02-01 |
2005-06-13 |
Astrazeneca Ab |
Quinazoline compounds
|
WO2003082271A2
(en)
*
|
2002-04-03 |
2003-10-09 |
Astrazeneca Ab |
Indole derivatives having anti-angiogenetic activity
|
TW200307542A
(en)
|
2002-05-30 |
2003-12-16 |
Astrazeneca Ab |
Novel compounds
|
SE0201635D0
(sv)
|
2002-05-30 |
2002-05-30 |
Astrazeneca Ab |
Novel compounds
|
SE0202241D0
(sv)
|
2002-07-17 |
2002-07-17 |
Astrazeneca Ab |
Novel Compounds
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
DE60318219T2
(de)
|
2002-08-24 |
2009-01-15 |
Astrazeneca Ab |
PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
EP1578755B1
(en)
|
2002-12-24 |
2007-08-22 |
AstraZeneca AB |
Phosphonooxy quinazoline derivatives and their pharmaceutical use
|
SE0301010D0
(sv)
|
2003-04-07 |
2003-04-07 |
Astrazeneca Ab |
Novel compounds
|
EP1479677A1
(en)
*
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
New indole derivatives as factor xa inhibitors
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
SE0302232D0
(sv)
|
2003-08-18 |
2003-08-18 |
Astrazeneca Ab |
Novel Compounds
|
SA04250253B1
(ar)
|
2003-08-21 |
2009-11-10 |
استرازينيكا ايه بي |
احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
|
SI1682138T1
(sl)
|
2003-11-19 |
2011-04-29 |
Array Biopharma Inc |
HETEROCIKLIÄŚNI INHIBITORJI MEK-a
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
RU2397168C2
(ru)
|
2004-01-05 |
2010-08-20 |
Астразенека Аб |
Производные тиофена в качестве ингибиторов снк 1
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0415320D0
(en)
|
2004-07-08 |
2004-08-11 |
Astrazeneca Ab |
Novel compounds
|
GB0418830D0
(en)
|
2004-08-24 |
2004-09-22 |
Astrazeneca Ab |
Novel compounds
|
PT1809624E
(pt)
|
2004-08-28 |
2014-01-14 |
Astrazeneca Ab |
Derivados de pirimidina sulfonamida como moduladores do recetor de quimiocina
|
PL1817282T3
(pl)
|
2004-11-23 |
2011-11-30 |
Astrazeneca Ab |
Pochodne kwasu fenoksyoctowego użyteczne do leczenia chorób układu oddechowego
|
DK1838733T3
(da)
|
2004-12-21 |
2011-11-28 |
Medimmune Ltd |
Antistoffer rettet mod angiopoietin-2 og anvendelser deraf
|
GB0500604D0
(en)
|
2005-01-13 |
2005-02-16 |
Astrazeneca Ab |
Novel process
|
ES2375735T3
(es)
|
2005-02-04 |
2012-03-05 |
Astrazeneca Ab |
Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
|
AU2006299902B2
(en)
|
2005-05-18 |
2012-11-01 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
MX2008000821A
(es)
|
2005-07-21 |
2008-03-19 |
Astrazeneca Ab |
Nuevos derivados de piperidina.
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
WO2007034881A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
WO2007034882A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
EP1939202A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW COMPOUND OF ADENINE
|
EP1939200A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
JPWO2007034917A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規なアデニン化合物
|
TW200745003A
(en)
|
2005-10-06 |
2007-12-16 |
Astrazeneca Ab |
Novel compounds
|
JP5155171B2
(ja)
|
2005-10-06 |
2013-02-27 |
アストラゼネカ・アクチエボラーグ |
新規化合物
|
EP1945631B8
(en)
|
2005-10-28 |
2013-01-02 |
AstraZeneca AB |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
PT1971601E
(pt)
|
2005-11-15 |
2010-01-26 |
Array Biopharma Inc |
Derivados de n4-fenil-quinazolina-4-amina e compostos relacionados como inibidores de tirosina quinases receptoras do tipo i erbb para o tratamento de doenças hiperproliferativas
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
RU2492185C2
(ru)
|
2005-12-13 |
2013-09-10 |
Астразенека Аб |
Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
|
EP1963259B1
(en)
|
2005-12-15 |
2012-02-15 |
AstraZeneca AB |
Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CN102558021A
(zh)
|
2006-05-26 |
2012-07-11 |
阿斯利康(瑞典)有限公司 |
联芳基或芳基-杂芳基取代的吲哚类化合物
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
MY148688A
(en)
|
2006-08-23 |
2013-05-31 |
Kudos Pharm Ltd |
2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
EP2121137B1
(en)
|
2006-12-19 |
2012-04-25 |
AstraZeneca AB |
Quinuclidinol derivatives as muscarinic receptor antagonists
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
AR065784A1
(es)
|
2007-03-20 |
2009-07-01 |
Dainippon Sumitomo Pharma Co |
Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
|
JPWO2008114819A1
(ja)
|
2007-03-20 |
2010-07-08 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
UA99459C2
(xx)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
ПОХІДНІ 9-(ПІРАЗОЛ-3-ІЛ)-9H-ПУРИН-2-АМІНУ І 3-(ПІРАЗОЛ-3-ІЛ)-3H-ІМІДАЗО$4,5-b]ПІРИДИН-5-АМІНУ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ РАКУ$ПРОИЗВОДНЫЕ 9-(ПИРАЗОЛ-3-ИЛ)-9H-ПУРИН-2-АМИНА И 3-(ПИРАЗОЛ-3-ИЛ)-3H-ИМИДАЗО$4,5-b]ПИРИДИН-5-АМИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(xx)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Біфенілоксипропанова кислота як модулятор crth2 і інтермедіати$бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
EP2207788A1
(en)
|
2007-10-04 |
2010-07-21 |
AstraZeneca AB |
Steroidal [3, 2-c]pyrazole compounds, with glucocorticoid activity
|
KR101494734B1
(ko)
|
2007-10-11 |
2015-02-26 |
아스트라제네카 아베 |
단백질 키나제 b 억제제로서 피롤로[2,3-d]피리미딘 유도체
|
AU2008326251B2
(en)
|
2007-11-21 |
2014-03-06 |
Mateon Therapeutics, Inc. |
Method for treating hematopoietic neoplasms
|
KR101620539B1
(ko)
|
2007-12-21 |
2016-05-13 |
메디뮨 리미티드 |
인터루킨-4 수용체 알파(IL-4Rα)에 대한 결합 구성원-173
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
NZ586872A
(en)
|
2008-02-06 |
2012-03-30 |
Astrazeneca Ab |
Spirocyclic amide compounds
|
CN101952287B
(zh)
|
2008-02-28 |
2013-11-27 |
默克专利有限公司 |
蛋白激酶抑制剂及其应用
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
PT2297106E
(pt)
|
2008-05-27 |
2014-09-29 |
Astrazeneca Ab |
Derivados de fenoxipiridinilamida e seu uso no tratamento de estados de doença mediados por pde4
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
TWI461423B
(zh)
|
2008-07-02 |
2014-11-21 |
Astrazeneca Ab |
用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
US8192738B2
(en)
|
2008-09-19 |
2012-06-05 |
Medimmune, Llc |
Targeted antibodies directed to DLL4
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
BRPI0923504A2
(pt)
|
2008-12-11 |
2020-05-26 |
Axcentua Pharmaceuticals Ab |
Formas cristalinas de genisteína.
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
ES2550101T3
(es)
|
2008-12-17 |
2015-11-04 |
Merck Patent Gmbh |
Inhibidores de proteína quinasa de benzonaftiridinona tricíclica modificada con anillo C y su uso
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
ES2603208T3
(es)
|
2008-12-18 |
2017-02-24 |
Merck Patent Gmbh |
Azaindoles tricíclicos
|
UY32351A
(es)
|
2008-12-22 |
2010-07-30 |
Astrazeneca Ab |
Compuestos de pirimidinil indol para uso como inhibidores de atr
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
PE20120603A1
(es)
|
2009-02-10 |
2012-06-14 |
Astrazeneca Ab |
Derivados de triazolo[4,3-b]piridazina y sus usos para el cancer de prostata
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
EP2483244A1
(en)
|
2009-10-02 |
2012-08-08 |
AstraZeneca AB |
2-pyridone compounds used as inhibitors of neutrophil elastase
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
AR079050A1
(es)
|
2009-11-18 |
2011-12-21 |
Astrazeneca Ab |
Compuestos benzoimidazolicos y sus usos
|
KR101934071B1
(ko)
|
2009-11-24 |
2019-01-02 |
메디뮨 리미티드 |
B7―h1에 대한 표적화된 결합 물질
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
CA2784075A1
(en)
|
2009-12-14 |
2011-06-23 |
Merck Patent Gmbh |
Inhibitors of sphingosine kinase
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
CN102639513A
(zh)
|
2009-12-17 |
2012-08-15 |
默克专利有限公司 |
鞘氨醇激酶抑制剂
|
ES2857626T3
(es)
|
2010-01-15 |
2021-09-29 |
Suzhou Neupharma Co Ltd |
Ciertas entidades químicas, composiciones y métodos
|
WO2011089416A1
(en)
|
2010-01-19 |
2011-07-28 |
Astrazeneca Ab |
Pyrazine derivatives
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
US20130059916A1
(en)
|
2010-05-26 |
2013-03-07 |
Stephane Rocchi |
Biguanide compounds and its use for treating cancer
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
TW201219383A
(en)
|
2010-08-02 |
2012-05-16 |
Astrazeneca Ab |
Chemical compounds
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
US9018197B2
(en)
|
2010-08-28 |
2015-04-28 |
Suzhou Neupharma Co. Ltd. |
Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
WO2012067268A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
ES2575688T3
(es)
|
2010-12-16 |
2016-06-30 |
Sumitomo Dainippon Pharma Co., Ltd. |
Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
|
JP5978226B2
(ja)
|
2010-12-17 |
2016-08-24 |
大日本住友製薬株式会社 |
プリン誘導体
|
BR112013015508B1
(pt)
|
2010-12-20 |
2022-04-05 |
Medimmune Limited |
Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
|
EP2670763B1
(en)
|
2011-02-02 |
2018-08-01 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions, and methods
|
WO2012110774A1
(en)
|
2011-02-17 |
2012-08-23 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
WO2012110773A1
(en)
|
2011-02-17 |
2012-08-23 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
UY34013A
(es)
|
2011-04-13 |
2012-11-30 |
Astrazeneca Ab |
?compuestos de cromenona con actividad anti-tumoral?.
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
CU24292B1
(es)
|
2011-07-12 |
2017-12-08 |
Astrazeneca Ab |
N-(6-((2r, 3s)- 3,4- dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio) pirimidin-4-il)-3- metilacetidina-1-sulfonamida como modulador del receptor de quimiocina
|
WO2013014448A1
(en)
|
2011-07-27 |
2013-01-31 |
Astrazeneca Ab |
2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
CN104053442B
(zh)
|
2011-08-26 |
2017-06-23 |
润新生物公司 |
某些化学实体、组合物及方法
|
WO2013033250A1
(en)
|
2011-09-01 |
2013-03-07 |
Xiangping Qian |
Certain chemical entities, compositions, and methods
|
CN115403531A
(zh)
|
2011-09-14 |
2022-11-29 |
润新生物公司 |
作为激酶抑制剂的化学实体、组合物及方法
|
WO2013043935A1
(en)
|
2011-09-21 |
2013-03-28 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
EP2760458B1
(en)
|
2011-09-29 |
2017-06-14 |
The University of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
US9249111B2
(en)
|
2011-09-30 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-RAF kinase inhibitors
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
EP2806874B1
(en)
|
2012-01-25 |
2017-11-15 |
Neupharma, Inc. |
Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
|
AU2012367141B2
(en)
|
2012-01-28 |
2016-12-22 |
Merck Patent Gmbh |
Triazolo[4,5-d]pyrimidine derivatives
|
KR20140121477A
(ko)
|
2012-02-09 |
2014-10-15 |
메르크 파텐트 게엠베하 |
Tank 및 parp 저해체로서의 테트라히드로-퀴나졸리논
|
RU2622034C2
(ru)
|
2012-02-09 |
2017-06-09 |
Мерк Патент Гмбх |
ПРОИЗВОДНЫЕ ФУРО[3,2-В]- И ТИЕНО[3,2-В]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ TBK1 И IKKε
|
AU2013224421B2
(en)
|
2012-02-21 |
2017-03-02 |
Merck Patent Gmbh |
8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
|
ES2606638T3
(es)
|
2012-02-21 |
2017-03-24 |
Merck Patent Gmbh |
Derivados de furopiridina
|
ES2552518T3
(es)
|
2012-02-21 |
2015-11-30 |
Merck Patent Gmbh |
Derivados cíclicos de diaminopiridina como inhibidores de Syk
|
US20150051202A1
(en)
|
2012-03-07 |
2015-02-19 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
NZ630489A
(en)
|
2012-03-28 |
2016-04-29 |
Merck Patent Gmbh |
Bicyclic pyrazinone derivatives
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
PE20142422A1
(es)
|
2012-04-05 |
2015-01-21 |
Hoffmann La Roche |
Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
|
WO2013165924A1
(en)
|
2012-04-29 |
2013-11-07 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
RS55062B1
(sr)
|
2012-05-04 |
2016-12-30 |
Merck Patent Gmbh |
Pirolotriazinon derivati
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
CA2879754C
(en)
|
2012-07-24 |
2021-02-16 |
Merck Patent Gmbh |
Hydroxystatin derivatives for the treatment of arthrosis
|
AU2013301865B2
(en)
|
2012-08-07 |
2017-08-17 |
Merck Patent Gmbh |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
MX362939B
(es)
|
2012-08-08 |
2019-02-27 |
Merck Patent Gmbh |
Derivados de (aza-)isoquinolinona.
|
US20160009686A1
(en)
|
2012-08-17 |
2016-01-14 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014047648A1
(en)
|
2012-09-24 |
2014-03-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
JP6276769B2
(ja)
|
2012-09-26 |
2018-02-07 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Parpインヒビターとしてのキナゾリノン誘導体
|
EP3354752B1
(en)
|
2012-11-05 |
2020-03-11 |
GMDx Co Pty Ltd |
Methods for determining the cause of somatic mutagenesis
|
US9725421B2
(en)
|
2012-11-12 |
2017-08-08 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
EP2920146B1
(en)
|
2012-11-16 |
2016-09-28 |
Merck Patent GmbH |
3-aminocyclopentane carboxamide derivatives
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
EP2951177B1
(en)
|
2013-01-31 |
2018-04-04 |
Neomed Institute |
Imidazopyridine compounds and uses thereof
|
CA2902080A1
(en)
|
2013-02-25 |
2014-08-28 |
Merck Patent Gmbh |
2-amino-3,4-dihydroquinazoline derivatives and the use thereof as cathepsin d inhibitors
|
JP6409007B2
(ja)
|
2013-03-05 |
2018-10-17 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
抗癌剤としての9−(アリールまたはヘテロアリール)−2−(ピラゾリル、ピロリジニルまたはシクロペンチル)アミノプリン誘導体
|
CN105142648A
(zh)
|
2013-03-15 |
2015-12-09 |
玛格塞蒂克斯公司 |
用于癌症的镁组合物及其用途
|
EP2972394A4
(en)
|
2013-03-15 |
2016-11-02 |
Sloan Kettering Inst Cancer |
HSP90 TARGETING CARDIAC IMAGING AND TREATMENT THEREOF
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
EP3004073A1
(en)
|
2013-06-07 |
2016-04-13 |
Université catholique de Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
AU2014302038B2
(en)
|
2013-06-25 |
2019-11-14 |
Epiaxis Therapeutics Pty Ltd |
Methods and compositions for modulating cancer stem cells
|
JP6559132B2
(ja)
|
2013-08-23 |
2019-08-14 |
ニューファーマ, インコーポレイテッド |
ある特定の化学的実体、組成物および方法
|
ES2851724T3
(es)
|
2013-09-18 |
2021-09-08 |
Epiaxis Therapeutics Pty Ltd |
Modulación de células madre
|
US20160298197A1
(en)
|
2013-10-01 |
2016-10-13 |
Queensland University Of Technology |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
CA2958704A1
(en)
|
2014-08-25 |
2016-03-03 |
University Of Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
EP3221701B1
(en)
|
2014-11-17 |
2021-03-31 |
The University of Queensland |
Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
WO2016133935A1
(en)
|
2015-02-17 |
2016-08-25 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
CN108349964B
(zh)
|
2015-08-04 |
2021-06-01 |
常州千红生化制药股份有限公司 |
N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物
|
EP3337495A4
(en)
|
2015-08-18 |
2019-04-10 |
Mateon Therapeutics, Inc. |
USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
|
CN108603231B
(zh)
|
2015-08-26 |
2023-06-30 |
Gmdx私人有限公司 |
检测癌症复发的方法
|
CN108883155A
(zh)
|
2016-02-01 |
2018-11-23 |
堪培拉大学 |
蛋白化合物及其用途
|
AU2017221268B2
(en)
|
2016-02-15 |
2024-02-15 |
Astrazeneca Ab |
Methods comprising fixed intermittent dosing of cediranib
|
RS63609B1
(sr)
|
2016-04-15 |
2022-10-31 |
Cancer Research Tech Ltd |
Heterociklična jedinjenja kao inhibitori ret kinaze
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
US10179787B2
(en)
|
2016-07-29 |
2019-01-15 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
CA3033370A1
(en)
|
2016-08-15 |
2018-02-22 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
CA3037605A1
(en)
|
2016-09-22 |
2018-03-29 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
AU2017372722B2
(en)
|
2016-12-05 |
2021-09-09 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups
|
CA3051604A1
(en)
|
2017-02-01 |
2018-08-09 |
Aucentra Therapeutics Pty Ltd |
Derivatives of n-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
US10703723B2
(en)
|
2017-03-09 |
2020-07-07 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
US11161839B2
(en)
|
2017-05-26 |
2021-11-02 |
The Institute Of Cancer Research: Royal Cancer Hospital |
2-quinolone derived inhibitors of BCL6
|
ES2897200T3
(es)
|
2017-05-31 |
2022-02-28 |
Amplio Pharma Ab |
Una composición farmacéutica que comprende una combinación de metotrexato y novobiocina, y el uso de la composición en terapia
|
US11400160B2
(en)
|
2017-07-05 |
2022-08-02 |
E.P.O.S Iasis Research And Development Limited |
Multifunctional conjugates
|
AU2018309265B2
(en)
|
2017-08-01 |
2022-06-02 |
Merck Patent Gmbh |
Thiazolopyridine derivatives as adenosine receptor antagonists
|
US11447505B1
(en)
|
2017-08-18 |
2022-09-20 |
Cancer Research Technology Limited |
Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
|
TWI791593B
(zh)
|
2017-08-21 |
2023-02-11 |
德商馬克專利公司 |
做為腺苷受體拮抗劑之苯并咪唑衍生物
|
ES2964026T3
(es)
|
2017-08-21 |
2024-04-03 |
Merck Patent Gmbh |
Derivados de quinoxalina como antagonistas de receptores de adenosina
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
RU2020118594A
(ru)
|
2017-11-06 |
2021-12-09 |
Рапт Терапьютикс, Инк. |
Противораковые агенты
|
EP3488868B1
(en)
|
2017-11-23 |
2023-09-13 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
EP3740484A4
(en)
|
2018-01-15 |
2021-06-09 |
Aucentra Holdings Pty Ltd |
5- (PYRIMIDIN-4-YL) THIAZOL-2-YL-UREA DERIVATIVES AS THERAPEUTICS
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
IL276295B2
(en)
|
2018-01-26 |
2024-02-01 |
Rapt Therapeutics Inc |
Modulators of chemokine receptors and their uses
|
US11465975B2
(en)
|
2018-02-08 |
2022-10-11 |
Neupharma, Inc |
Certain chemical entities, compositions, and methods
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
PT3774817T
(pt)
|
2018-04-13 |
2023-03-09 |
The Institute Of Cancer Res Royal Cancer Hospital |
Inibidores de bcl6
|
JP7427655B2
(ja)
|
2018-04-27 |
2024-02-05 |
スプルース バイオサイエンシーズ,インク. |
精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法
|
EP3802519A1
(en)
|
2018-06-04 |
2021-04-14 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
EP3802544A1
(en)
|
2018-06-05 |
2021-04-14 |
RAPT Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
CN112654612A
(zh)
|
2018-09-18 |
2021-04-13 |
苏州赞荣医药科技有限公司 |
作为抗肿瘤剂的喹唑啉衍生物
|
US11084829B2
(en)
|
2018-09-24 |
2021-08-10 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
|
AU2019362747A1
(en)
*
|
2018-10-15 |
2021-06-03 |
Gero Pte. Ltd. |
PFKFB3 inhibitors and their uses
|
SG11202104081XA
(en)
|
2018-10-25 |
2021-05-28 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists
|
EP3870582B1
(en)
|
2018-10-25 |
2023-07-19 |
Merck Patent GmbH |
5-azaindazole derivatives as adenosine receptor antagonists
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
US11033547B2
(en)
|
2019-03-07 |
2021-06-15 |
Merck Patent Gmbh |
Carboxamide-pyrimidine derivatives as SHP2 antagonists
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
JP2022528562A
(ja)
|
2019-04-05 |
2022-06-14 |
ストーム・セラピューティクス・リミテッド |
Mettl3阻害化合物
|
WO2020210384A1
(en)
|
2019-04-08 |
2020-10-15 |
Merck Patent Gmbh |
Pyrimidinone derivatives as shp2 antagonists
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
JP2022545930A
(ja)
|
2019-08-31 |
2022-11-01 |
上海奕拓醫藥科技有限責任公司 |
Fgfr阻害剤とするピラゾール類誘導体及びその調製方法
|
AU2020348489A1
(en)
|
2019-09-20 |
2022-05-05 |
Ideaya Biosciences, Inc. |
4-substituted indole and indazole sulfonamido derivatives as PARG inhibitors
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
AU2020394867A1
(en)
|
2019-12-02 |
2022-05-26 |
Storm Therapeutics Limited |
Polyheterocyclic compounds as METTL3 inhibitors
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202008201D0
(en)
|
2020-06-01 |
2020-07-15 |
Neophore Ltd |
Inhibitor compounds
|
GB202012482D0
(en)
|
2020-08-11 |
2020-09-23 |
Univ Of Huddersfield |
Novel compounds and therapeutic uses thereof
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
US20230391770A1
(en)
|
2020-10-06 |
2023-12-07 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
JP2024517872A
(ja)
|
2021-05-03 |
2024-04-23 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
HER2を標的にするFc抗原結合性フラグメント-薬物抱合体
|
KR20220156448A
(ko)
|
2021-05-17 |
2022-11-25 |
에이치케이이노엔 주식회사 |
벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
WO2022248380A1
(en)
|
2021-05-25 |
2022-12-01 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
GB202110373D0
(en)
|
2021-07-19 |
2021-09-01 |
Neophore Ltd |
Inhibitor compounds
|
CA3225500A1
(en)
|
2021-10-04 |
2023-04-13 |
Ulrich Luecking |
Parg inhibitory compounds
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
GB202117224D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Inhibitor compounds
|
GB202117225D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Protac compounds
|
WO2023131690A1
(en)
|
2022-01-10 |
2023-07-13 |
Merck Patent Gmbh |
Substituted heterocycles as hset inhibitors
|
GB202202006D0
(en)
|
2022-02-15 |
2022-03-30 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Anti-cancer treatment
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
WO2023196432A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
WO2023218201A1
(en)
|
2022-05-11 |
2023-11-16 |
Cancer Research Technology Limited |
Ikk inhibitors
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
WO2024094962A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
WO2024099898A1
(en)
|
2022-11-07 |
2024-05-16 |
Merck Patent Gmbh |
Substituted bi-and tricyclic hset inhibitors
|